NASDAQ:SPROSpero Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Spero Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.72 +0.21 (+2.80 %) (As of 04/9/2020 09:20 AM ET) Add Compare Share Today's Range$7.51Now: $7.72▼$8.0050-Day Range$5.27MA: $8.01▼$9.6252-Week Range$5.25Now: $7.72▼$14.48Volume127,744 shsAverage Volume105,642 shsMarket Capitalization$156.95 millionP/E RatioN/ADividend YieldN/ABeta1.51 ProfileAnalyst RatingsAdvanced ChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is phase I clinical trial to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic, which is in phase I clinical trial for the treatment of pulmonary non-tuberculous mycobacterial infections. Spero Therapeutics, Inc. has collaboration with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries, as well as has option to rights to SPR741 in the territory. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingSpero Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $25.75, Spero Therapeutics has a potential upside of 233.5% from its current price of $7.72.Amount of Analyst CoverageSpero Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesSpero Therapeutics has received 155 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSpero Therapeutics has received 140 “underperform” votes. (Add your “underperform” vote.)Community SentimentSpero Therapeutics has received 52.54% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Spero Therapeutics and other stocks. Vote “Outperform” if you believe SPRO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SPRO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSpero Therapeutics does not currently pay a dividend.Dividend GrowthSpero Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spero Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 18.34% of the stock of Spero Therapeutics is held by insiders.Percentage Held by Institutions47.69% of the stock of Spero Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Spero Therapeutics are expected to decrease by -14.52% in the coming year, from ($4.27) to ($3.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spero Therapeutics is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spero Therapeutics is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpero Therapeutics has a P/B Ratio of 1.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.42 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SPRO Previous Symbol CUSIPN/A CIK1701108 Webhttp://www.sperotherapeutics.com/ Phone857-242-1600Debt Debt-to-Equity Ratio0.06 Current Ratio3.58 Quick Ratio3.58Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.15 million Price / Sales8.65 Cash FlowN/A Price / Cash FlowN/A Book Value$3.90 per share Price / Book1.98Profitability EPS (Most Recent Fiscal Year)($3.35) Net Income$-60,920,000.00 Net Margins-336.96% Return on Equity-62.62% Return on Assets-52.51%Miscellaneous Employees41 Outstanding Shares20,330,000Market Cap$156.95 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive SPRO News and Ratings via Email Sign-up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SPRO Rates by TradingView Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions How has Spero Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Spero Therapeutics' stock was trading at $7.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SPRO stock has decreased by 0.4% and is now trading at $7.72. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Spero Therapeutics? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Spero Therapeutics. When is Spero Therapeutics' next earnings date? Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Spero Therapeutics. How were Spero Therapeutics' earnings last quarter? Spero Therapeutics Inc (NASDAQ:SPRO) posted its earnings results on Monday, March, 16th. The company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.05) by $0.27. The company had revenue of $3.63 million for the quarter, compared to analysts' expectations of $3.54 million. Spero Therapeutics had a negative net margin of 336.96% and a negative return on equity of 62.62%. View Spero Therapeutics' earnings history. What price target have analysts set for SPRO? 5 brokerages have issued 1 year price objectives for Spero Therapeutics' stock. Their forecasts range from $20.00 to $35.00. On average, they anticipate Spero Therapeutics' stock price to reach $25.75 in the next twelve months. This suggests a possible upside of 233.5% from the stock's current price. View analysts' price targets for Spero Therapeutics. What are Wall Street analysts saying about Spero Therapeutics stock? Here are some recent quotes from research analysts about Spero Therapeutics stock: 1. According to Zacks Investment Research, "Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States. " (2/28/2020) 2. HC Wainwright analysts commented, "916-3963, POS Risk-adj value Full value SPR994 (oral carbapenem) – cUTI 62% $22.87 $36.88 Shares outstanding 18,656 S/O as of SPR741 (IV potentiator) – MDR Gram (-) $3.22 $3.22 Current share price $9.23 Discount rate 14.5% SPR720 (oral treatment) – NTM $1.34 $1.34." (8/12/2019) 3. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts for 2019+. Anticipated 2019 events include pharmacokinetic data from a lead-in cohort of 70 patients in 2H19 for SPR994 in the cUTI patient population, Phase 1 data for 1 data for SPR720." (5/9/2019) Has Spero Therapeutics been receiving favorable news coverage? News headlines about SPRO stock have been trending very negative on Thursday, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Spero Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutSpero Therapeutics. Are investors shorting Spero Therapeutics? Spero Therapeutics saw a drop in short interest during the month of February. As of February 28th, there was short interest totaling 439,800 shares, a drop of 42.5% from the February 13th total of 764,900 shares. Based on an average daily volume of 86,900 shares, the short-interest ratio is currently 5.1 days. Approximately 3.1% of the company's shares are short sold. View Spero Therapeutics' Current Options Chain. Who are some of Spero Therapeutics' key competitors? Some companies that are related to Spero Therapeutics include Collegium Pharmaceutical (COLL), Kadmon (KDMN), ImmunoGen (IMGN), Vanda Pharmaceuticals (VNDA), Akero Therapeutics (AKRO), Radius Health (RDUS), Basilea Pharmaceutica (BPMUF), ZIOPHARM Oncology (ZIOP), ANI Pharmaceuticals (ANIP), Nabriva Therapeutics (NBRV), Assembly Biosciences (ASMB), Emisphere Technologies (EMIS), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS) and Frequency Therapeutics (FREQ). What other stocks do shareholders of Spero Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Catalyst Pharmaceuticals (CPRX), Crispr Therapeutics (CRSP), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Allena Pharmaceuticals (ALNA), Avid Bioservices (CDMO), Fate Therapeutics (FATE), Viking Therapeutics (VKTX), Amicus Therapeutics (FOLD) and Galmed Pharmaceuticals (GLMD). Who are Spero Therapeutics' key executives? Spero Therapeutics' management team includes the following people: Mr. Ankit Mahadevia M.D., MBA, Co-Founder, CEO, Pres & Director (Age 38)Mr. Joel D. Sendek, CFO, Treasurer & Sec. (Age 52)Ms. Cristina Larkin, Chief Operating Officer (Age 49)Dr. Thomas R. Parr Jr., Chief Scientific Officer (Age 65)Ms. Sharon Klahre, Director of Investor Relations When did Spero Therapeutics IPO? (SPRO) raised $75 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel acted as the underwriters for the IPO and Oppenheimer & Co. was co-manager. What is Spero Therapeutics' stock symbol? Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO." How do I buy shares of Spero Therapeutics? Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Spero Therapeutics' stock price today? One share of SPRO stock can currently be purchased for approximately $7.72. How big of a company is Spero Therapeutics? Spero Therapeutics has a market capitalization of $156.95 million and generates $18.15 million in revenue each year. The company earns $-60,920,000.00 in net income (profit) each year or ($3.35) on an earnings per share basis. Spero Therapeutics employs 41 workers across the globe. View additional information about Spero Therapeutics. What is Spero Therapeutics' official website? The official website for Spero Therapeutics is http://www.sperotherapeutics.com/. How can I contact Spero Therapeutics? Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at 857-242-1600 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: Most Active Stocks
